Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
(Reprinted with permission from American Psychiatric Association, http://psychiatryonline.org/guidelines).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“The results support the concern that an increased risk for death continues if patients remain on antipsychotic medications and is not just a shortterm effect seen for 10–12 weeks after initiation of antipsychotic medication (Schneider et al. 2005).”
BackgroundSelf-citationPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · cited 1×
“2008), docosahexaenoic acid (Quinn et al. 2010), and Huperzine A (Rafii et al.”
BackgroundA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572
Self-citationHusebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B., & Aarsland, D. (2011) · BMJ · doi:10.1136/bmj.d4065 · Cited by 571
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532
Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Self-citationMeta-Analysis of Nonpharmacological Interventions for Neuropsychiatric Symptoms of Dementia
Brodaty, H., & Arasaratnam, C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11101529 · Cited by 479 · cited 1×
“Brodaty and Arasaratnam (2012) conducted a meta-analysis of studies evaluating the efficacy of interventions delivered by family caregivers to reduce neuropsychiatric symptoms.”
BackgroundRandomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Gitlin, L. N., Winter, L., Burke, J., Chernett, N., Dennis, M. P., & Hauck, W. W. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000300629.35408.94 · Cited by 362
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Selwood, A., Johnston, K., Katona, C., Lyketsos, C., & Livingston, G. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.10.025 · Cited by 342
Efficacy of Music Therapy in the Treatment of Behavioral and Psychiatric Symptoms of Dementia
Raglio, A., Bellelli, G., Traficante, D., Gianotti, M., Ubezio, M. C., Villani, D., & Trabucchi, M. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181630b6f · Cited by 333
Donepezil for the Treatment of Agitation in Alzheimer's Disease
Howard, R. J., Juszczak, E., Ballard, C. G., Bentham, P., Brown, R. G., Bullock, R., Burns, A. S., Holmes, C., Jacoby, R., Johnson, T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066583 · Cited by 327 · cited 1×
“In patients with Alzheimer’s disease who had clinically significant agitation and no response to a brief psychosocial treatment program, 272 subjects were randomly assigned to receive 10 mg/day of donepezil (128 patients) or placebo (131 patients) (Howard et al. 2007).”
MethodSultzer, D. L., Davis, S. M., Tariot, P. N., Dagerman, K. S., Lebowitz, B. D., Lyketsos, C. G., Rosenheck, R. A., Hsiao, J. K., Lieberman, J. A., Schneider, L. S., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111779 · Cited by 321
Self-citationMcGuinness, B., Todd, S., Passmore, P., & Bullock, R. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub3 · Cited by 315
Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291 · cited 1×
“A large randomized controlled trial on the use of pravastatin in 5,804 at-risk elderly patients found no difference between statins and placebo in the prevention of cognitive decline after a mean follow-up period of 42 months (Trompet et al. 2010).”
BackgroundNelson, J. C., & Devanand, D. P. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03355.x · Cited by 284
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Dichgans, M., Markus, H. S., Salloway, S., Verkkoniemi, A., Moline, M., Wang, Q., Posner, H., & Chabriat, H. S. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70046-2 · Cited by 264
Pollock, B. G., Mulsant, B. H., Rosen, J., Mazumdar, S., Blakesley, R. E., Houck, P. R., & Huber, K. A. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3180cc1ff5 · Cited by 257 · cited 1×
“2007), risperidone and citalopram (Pollock et al. 2007), and risperidone and escitalopram (Barak et al.”
BackgroundEffects of omega-3 fatty acids on cognitive performance: a meta-analysis
Mazereeuw, G., Lanctôt, K. L., Chau, S. A., Swardfager, W., & Herrmann, N. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.014 · Cited by 253
Sertraline for the treatment of depression in Alzheimer disease
Rosenberg, P. B., Martin, B. K., Frangakis, C., Mintzer, J. E., Weintraub, D., Porsteinsson, A. P., Schneider, L. S., Rabins, P. V., Munro, C. A., Meinert, C. L., et al. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181c796eb · Cited by 250 · cited 1×
“The other trial included 135 people with Alzheimer’s disease and depression and also failed to show benefit of sertraline (at a target dosage of 100 mg/day) in comparison with placebo (Rosenberg et al. 2010).”
BackgroundSelf-citationAkhondzadeh, S., Sabet, M. S., Harirchian, M. H., Togha, M., Cheraghmakani, H., Razeghi, S., Hejazi, S. S., Yousefi, M. H., Alimardani, R., Jamshidi, A., et al. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01133.x · Cited by 249
O'Connor, D. W., Ames, D., Gardner, B., & King, M. (2009) · International Psychogeriatrics · doi:10.1017/s1041610208007588 · Cited by 239
Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C.-K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70320-4 · Cited by 228
Spijker, A., Vernooij‐Dassen, M., Vasse, E., Adang, E., Wollersheim, H., Grol, R., & Verhey, F. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01705.x · Cited by 223 · cited 1×
“Spijker et al. (2008) conducted a systematic review with meta-analysis of high-quality studies, with a total of 9,043 patients, on the impact of caregiver support programs on delaying institutionalization and found that these programs reduced the odds of institutionalization (odds ratio=0.”
BackgroundGalantamine in Frontotemporal Dementia and Primary Progressive Aphasia
Kertesz, A., Morlog, D., Light, M., Blair, M., Davidson, W., Jesso, S., & Brashear, R. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000113034 · Cited by 217 · cited 1×
“In a more recent study, 36 patients with behavioral variety FTD and primary progressive aphasia were treated in an open-label fashion with galantamine for 18 weeks and then were randomly assigned to receive an additional 8 weeks of either galantamine or placebo (Kertesz et al. 2008).”
BackgroundDonepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., Pourcher, E., Gray, J., Thomas, G., Swartz, J., et al. (2012) · Movement Disorders · doi:10.1002/mds.25098 · Cited by 202
Physical activity programs for persons with dementia
Forbes, D., Forbes, S., Morgan, D. G., Markle-Reid, M., Wood, J., & Culum, I. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006489.pub2 · Cited by 194
Rosenberg, P. B., Lanctôt, K. L., Drye, L. T., Herrmann, N., Scherer, R. W., Bachman, D. L., Mintzer, J. E., & ADMET investigators (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08099 · Cited by 191
Galantamine treatment of vascular dementia: A randomized trial
Auchus, A. P., Brashear, H. R., Salloway, S., Korczyn, A. D., De Deyn, P. P., & Gassmann-Mayer, C. (2007) · Neurology · doi:10.1212/01.wnl.0000266625.31615.f6 · Cited by 189
Lin, P. W., Chan, W., Ng, B. F., & Lam, L. C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1688 · Cited by 185 · cited 1×
“2011); of reflexology, despite some encouraging small studies (Burns et al. 2011; Ernst 2009; Ernst et al. 2011; Hodgson and Andersen 2008; Lin et al. 2007); of transcranial magnetic stimulation, despite some positive smaller studies (Ahmed et al.”
ResultCooke, M. L., Moyle, W., Shum, D. H. K., Harrison, S. D., & Murfield, J. E. (2010) · Aging & Mental Health · doi:10.1080/13607861003713190 · Cited by 177
Fox, C., Crugel, M., Maidment, I., Auestad, B. H., Coulton, S., Treloar, A., Ballard, C., Boustani, M., Katona, C., & Livingston, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035185 · Cited by 173
Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172
Burns, A., Perry, E., Holmes, C., Francis, P., Morris, J., Howes, M.-J. R., Chazot, P., Lees, G., & Ballard, C. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000324438 · Cited by 149
Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802328142 · Cited by 147
O'Connor, D. W., Ames, D., Gardner, B., & King, M. (2009) · International Psychogeriatrics · doi:10.1017/s1041610208008223 · Cited by 126
A systematic review of intervention studies about anxiety in caregivers of people with dementia
Cooper, C., Balamurali, T. B. S., Selwood, A., & Livingston, G. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1656 · Cited by 117
Non‐pharmacological management of behavioural symptoms in nursing homes
Deudon, A., Maubourguet, N., Gervais, X., Leone, E., Brocker, P., Carcaillon, L., Riff, S., Lavallart, B., & Robert, P. H. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2275 · Cited by 102
Au, A., Li, S., Lee, K., Leung, P., Pan, P.-C., Thompson, L., & Gallagher-Thompson, D. (2010) · Patient Education and Counseling · doi:10.1016/j.pec.2009.06.005 · Cited by 91
Kurz, A. F., Leucht, S., & Lautenschlager, N. T. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211001001 · Cited by 82 · cited 1×
“Kurz et al. (2011) conducted a systematic review of randomized controlled trials evaluating cognition-focused interventions in participants with mild cognitive impairment or dementia and used meta-analytic strategies to calculate effect sizes.”
BackgroundTherapeutic Touch and Agitation in Individuals With Alzheimer's Disease
Hawranik, P., Johnston, P., & Deatrich, J. (2008) · Western Journal of Nursing Research · doi:10.1177/0193945907305126 · Cited by 81 · cited 1×
“In addition, a relatively large study of therapeutic touch showed positive results for restlessness but not for aggression in nursing home patients with dementia (Hawranik et al. 2008; Woods et al. 2009).”
BackgroundThe Effect of Therapeutic Touch on Behavioral Symptoms and Cortisol in Persons with Dementia
Woods, D. L., Beck, C., & Sinha, K. (2009) · Forschende Komplementärmedizin / Research in Complementary Medicine · doi:10.1159/000220479 · Cited by 70 · cited 1×
“In addition, a relatively large study of therapeutic touch showed positive results for restlessness but not for aggression in nursing home patients with dementia (Hawranik et al. 2008; Woods et al. 2009).”
Background
Cited by
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Self-citation(2018) · Europe PMC (PubMed Central) · Cited by 196
James, T., Mukadam, N., Sommerlad, A., Pour, H. R., Knowles, M., Azocar, I., & Livingston, G. (2022) · PLOS Medicine · doi:10.1371/journal.pmed.1003860 · Cited by 23
MiRNA-501-3p and miRNA-502-3p: a promising biomarker panel for Alzheimer’s disease
Devara, D., Sharma, B., Goyal, G., Rodarte, D., Kulkarni, A., Tinu, N., Pai, A., & Kumar, S. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70389 · Cited by 22
Metadata
- Authors
- Rabins, P. V., Rovner, B. W., Rummans, T., Schneider, L. S., & Tariot, P. N.
- Venue
- Focus
- Published
- 2017-01
- Volume
- 15
- Issue
- 1
- Pages
- 110-128
- ISSN
- 1541-4094 (ISSN-L)
- 1541-4108
- OpenAlex
- W2572073451
- Cited by
- 72
- References
- 56
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.